Home Away from Home: Cancer Treatment and Lodging Help

To save money, more and more procedures are performed today on an out-patient basis, often including same-day surgical care. On-going treatments, like radiation or chemotherapy, may not require overnight hospitalization, but usually involve a series of exhausting treatments for patients, especially if daily-round trips to the hospital are required.


Even when medical treatment is covered by insurance, living expenses are not. Families often cannot afford expensive hotels or motels. The National Association of Hospital Hospitality Houses, Inc. is a caring association of more than 150 nonprofit organizations located throughout the U.S. that provide family-centered lodging and support services to families and their loved ones who are receiving medical treatment far from their home communities.


To reduce healthcare costs, NAHHH member/houses offer inexpensive accommodations (usually $5 to $15, sometimes free) during hospitalizations, before and after surgery, and during repeated visits. For more information, check out www.nahhh.org

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap